VRAX Valuation
Virax Biolabs Group Ltd
$
0.604
- Overview
- Forecast
- Valuation
- Earnings
VRAX Relative Valuation
VRAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VRAX is overvalued; if below, it's undervalued.
Historical Valuation
Virax Biolabs Group Ltd (VRAX) is now in the Fair zone, suggesting that its current forward PS ratio of 65.76 is considered Fairly compared with the five-year average of -3.45. The fair price of Virax Biolabs Group Ltd (VRAX) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：0.57
Fair
-0.57
PE
1Y
3Y
5Y
Trailing
Forward
-2.02
EV/EBITDA
Virax Biolabs Group Ltd. (VRAX) has a current EV/EBITDA of -2.02. The 5-year average EV/EBITDA is -1.43. The thresholds are as follows: Strongly Undervalued below -13.40, Undervalued between -13.40 and -7.42, Fairly Valued between 4.55 and -7.42, Overvalued between 4.55 and 10.54, and Strongly Overvalued above 10.54. The current Forward EV/EBITDA of -2.02 falls within the Historic Trend Line -Fairly Valued range.
0.20
EV/EBIT
Virax Biolabs Group Ltd. (VRAX) has a current EV/EBIT of 0.20. The 5-year average EV/EBIT is -1.51. The thresholds are as follows: Strongly Undervalued below -13.32, Undervalued between -13.32 and -7.42, Fairly Valued between 4.39 and -7.42, Overvalued between 4.39 and 10.29, and Strongly Overvalued above 10.29. The current Forward EV/EBIT of 0.20 falls within the Historic Trend Line -Fairly Valued range.
65.76
PS
Virax Biolabs Group Ltd. (VRAX) has a current PS of 65.76. The 5-year average PS is 45.34. The thresholds are as follows: Strongly Undervalued below -198.89, Undervalued between -198.89 and -76.77, Fairly Valued between 167.46 and -76.77, Overvalued between 167.46 and 289.58, and Strongly Overvalued above 289.58. The current Forward PS of 65.76 falls within the Historic Trend Line -Fairly Valued range.
-0.53
P/OCF
Virax Biolabs Group Ltd. (VRAX) has a current P/OCF of -0.53. The 5-year average P/OCF is -0.11. The thresholds are as follows: Strongly Undervalued below -0.72, Undervalued between -0.72 and -0.42, Fairly Valued between 0.19 and -0.42, Overvalued between 0.19 and 0.49, and Strongly Overvalued above 0.49. The current Forward P/OCF of -0.53 falls within the Undervalued range.
0.00
P/FCF
Virax Biolabs Group Ltd. (VRAX) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Virax Biolabs Group Ltd (VRAX) has a current Price-to-Book (P/B) ratio of 0.44. Compared to its 3-year average P/B ratio of 1.25 , the current P/B ratio is approximately -65.24% higher. Relative to its 5-year average P/B ratio of 2.15, the current P/B ratio is about -79.75% higher. Virax Biolabs Group Ltd (VRAX) has a Forward Free Cash Flow (FCF) yield of approximately -196.46%. Compared to its 3-year average FCF yield of -128.51%, the current FCF yield is approximately 52.87% lower. Relative to its 5-year average FCF yield of -123.30% , the current FCF yield is about 59.33% lower.
0.44
P/B
Median3y
1.25
Median5y
2.15
-196.46
FCF Yield
Median3y
-128.51
Median5y
-123.30
Competitors Valuation Multiple
The average P/S ratio for VRAX's competitors is 11.77, providing a benchmark for relative valuation. Virax Biolabs Group Ltd Corp (VRAX) exhibits a P/S ratio of 65.76, which is 458.65% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of VRAX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of VRAX in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is Virax Biolabs Group Ltd (VRAX) currently overvalued or undervalued?
Virax Biolabs Group Ltd (VRAX) is now in the Fair zone, suggesting that its current forward PS ratio of 65.76 is considered Fairly compared with the five-year average of -3.45. The fair price of Virax Biolabs Group Ltd (VRAX) is between to according to relative valuation methord.
What is Virax Biolabs Group Ltd (VRAX) fair value?
How does VRAX's valuation metrics compare to the industry average?
What is the current P/B ratio for Virax Biolabs Group Ltd (VRAX) as of Sep 04 2025?
What is the current FCF Yield for Virax Biolabs Group Ltd (VRAX) as of Sep 04 2025?
What is the current Forward P/E ratio for Virax Biolabs Group Ltd (VRAX) as of Sep 04 2025?